eyenovia-logo 3

Investor Relations

Investor Relations

Corporate Profile

Eyenovia is a late-stage ophthalmic biopharmaceutical company developing breakthrough treatments for front and back-of-the-eye diseases, which are made possible by the company’s transformative, high precision ophthalmic delivery platform. Eyenovia’s pipeline is currently focused on the development of four programs including myopia (nearsightedness) progression, glaucoma and other eye diseases

Copyright West LLC. Minimum 15 minutes delayed.

Recent News Releases
Eyenovia to Participate in Multiple Upcoming Medical Meetings
Eyenovia to Present at Two Upcoming Investor Conferences
Eyenovia Reports Second Quarter 2019 Financial Results
Upcoming Events
Date Title
Wednesday, October 23, 2019 from 7:30 AM to 9:30 AM EDT
Friday, October 25, 2019 from 1:00 PM to 3:00 PM EDT